Article in Cancer prevention research (Philadelphia, Pa.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
31 authors.
Sayada Zartasha KazmiDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-9267-3637
Aesun ShinDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-6426-1969
Sarah K AbeDivision of Prevention, National Cancer Center Institute for Cancer Control, Tokyo, Japan.ORCID 0000-0003-3991-2739
Md Rashedul IslamDivision of Prevention, National Cancer Center Institute for Cancer Control, Tokyo, Japan.ORCID 0000-0003-3568-0870
Md Shafiur RahmanDivision of Prevention, National Cancer Center Institute for Cancer Control, Tokyo, Japan.ORCID 0000-0003-1911-6807
Eiko SaitoInstitute for Global Health Policy Research, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-4550-9631
Sooyoung ChoMedical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-9605-9685
Ryoko KatagiriDivision of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan.ORCID 0000-0002-4867-2450
Melissa A MerrittThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia.ORCID 0000-0002-5067-6119
Ji-Yeob ChoiDepartment of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.ORCID 0000-0001-5365-8189
Xiao-Ou ShuDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0711-8314
Norie SawadaDivision of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan.ORCID 0000-0002-9936-1476
Akiko TamakoshiDepartment of Public Health, Hokkaido University Faculty of Medicine, Sapporo, Japan.ORCID 0000-0002-9761-3879
Atsushi HozawaTohoku University Graduate School of Medicine, Miyagi Prefecture, Japan.ORCID 0000-0002-8031-8523
Seiki KanemuraTohoku University Graduate School of Medicine, Miyagi Prefecture, Japan.ORCID 0000-0003-0454-0322
Jeongseon KimGraduate School of Cancer Science and Policy, National Cancer Center, Goyang-si, Republic of Korea.ORCID 0000-0002-0889-2686
Yumi SugawaraTohoku University Graduate School of Medicine, Miyagi Prefecture, Japan.ORCID 0000-0002-0197-6772
Sue K ParkDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0001-5002-9707
Hui CaiDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-6182-966X
Shoichiro TsuganeDivision of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan.ORCID 0000-0003-4105-2774
Takashi KimuraDepartment of Public Health, Hokkaido University Faculty of Medicine, Sapporo, Japan.ORCID 0000-0002-6839-8962
Habibul AhsanDepartment of Public Health Sciences, University of Chicago, Chicago, Illinois.ORCID 0000-0001-9808-377X
Paolo BoffettaStony Brook Cancer Center, Stony Brook University, Stony Brook, New York.ORCID 0000-0002-3811-2791
Kee Seng ChiaSaw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-0629-5570
Keitaro MatsuoDivision Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID 0000-0003-1761-6314
You-Lin QiaoSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0001-6380-0871
Nathaniel RothmanOccupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-6924-0895
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-1226-070X
Manami InoueHitotsubashi Institute for Advanced Study, Hitotsubashi University, Tokyo, Japan.ORCID 0000-0003-1276-2398
Daehee KangDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0003-4031-5878
Funding
Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
Shanghai Womens Health StudyUM1CA182910 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2014 to 2018
$5.9M
Cancer Risk Reduction and Diet: A Cohort Study of WomenR37CA070867 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2009 to 2013
$4.7M
Ministry of Education, Culture, Sports, Science and Technology (MEXT)Ministry of Health and Welfare (MOHW) HA21C0140Ministry of Health, Labour and Welfare (MHLW)National Cancer Center Japan (NCC)National Cancer Center Japan (NCC) 2020-J-4National Cancer Center Japan (NCC) 23-A-31(toku)National Cancer Center Japan (NCC) 30-A-15National Cancer Center (NCC) 2210990National Research Foundation of Korea (NRF) 2016R1A2B4014552National Research Foundation of Korea (NRF) 2022R1A2C1004608NCI NIH HHS R37 CA070867NCI NIH HHS UM1 CA182910NIEHS NIH HHS 27303C0140NIEHS NIH HHS P30 ES027792U.S. Department of Energy (DOE)
6 · The paper itself
Abstract
Given the female predominance of thyroid cancer, particularly in the reproductive age range, female sex hormones have been proposed as an etiology; however, previous epidemiological studies have shown conflicting results. We conducted a pooled analysis using individual data from nine prospective cohorts in the Asia Cohort Consortium to explore the association between 10 female reproductive and hormonal factors and thyroid cancer risk. Using Cox proportional hazards models, cohort-specific hazard ratios (HR) and 95% confidence intervals (CI) were estimated and then pooled using a random-effects model. Analyses were stratified by country, birth years, smoking status, and body mass index, and thyroid cancer risk based on age of diagnosis was also examined. Among 259,649 women followed up for a mean of 17.2 years, 1,353 incident thyroid cancer cases were identified, with 88% (n = 1,140) being papillary thyroid cancer. Older age at first delivery (≥26 vs. 21-25 years) was associated with increased thyroid cancer risk (P-trend = 0.003; HR = 1.16; 95% CI, 1.03-1.31), particularly when diagnosed later in life (≥55 vs. < 55 years; P-trend = 0.003; HR = 1.19; 95% CI, 1.02-1.39). Among younger birth cohorts, women with more number of deliveries showed an increased thyroid cancer risk [P-trend = 0.0001, HR = 2.40; 95% CI, 1.12-5.18 (≥5 vs. 1-2 children)], and there was no substantial trend in older cohorts. Distinct patterns were observed for the number of deliveries and thyroid cancer risk across countries, with a significant positive association for Korea [P-trend = 0.0008, HR = 1.89; 95% CI, 1.21-2.94 (≥5 vs. 1-2 children)] and nonsignificant inverse associations for China and Japan. Contextual and macrosocial changes in reproductive factors in Asian countries may influence thyroid cancer risk. Prevention Relevance: This analysis of prospective cohort studies across three Asian countries highlights that older age at first birth is linked to increased thyroid cancer risk. As women delay motherhood, understanding these trends is vital for public health strategies addressing reproductive factors influencing thyroid cancer risk in these populations.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Reproductive and Hormonal Factors and Thyroid Cancer Risk: Pooled Analysis of Prospective Cohort Studies in the Asia Cohort Consortium. · full record | OpenQuestion